Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Share-based Compensation (2021 - 2025)

Historic Share-based Compensation for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $7.0 million.

  • Rxo's Share-based Compensation rose 1666.67% to $7.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $29.0 million, marking a year-over-year increase of 2608.7%. This contributed to the annual value of $29.0 million for FY2025, which is 2608.7% up from last year.
  • As of Q4 2025, Rxo's Share-based Compensation stood at $7.0 million, which was up 1666.67% from $8.0 million recorded in Q3 2025.
  • Rxo's 5-year Share-based Compensation high stood at $23.0 million for Q4 2022, and its period low was $2.0 million during Q4 2021.
  • For the 5-year period, Rxo's Share-based Compensation averaged around $6.2 million, with its median value being $6.0 million (2023).
  • Per our database at Business Quant, Rxo's Share-based Compensation surged by 105000.0% in 2022 and then crashed by 8695.65% in 2023.
  • Quarter analysis of 5 years shows Rxo's Share-based Compensation stood at $2.0 million in 2021, then skyrocketed by 1050.0% to $23.0 million in 2022, then crashed by 86.96% to $3.0 million in 2023, then surged by 100.0% to $6.0 million in 2024, then grew by 16.67% to $7.0 million in 2025.
  • Its last three reported values are $7.0 million in Q4 2025, $8.0 million for Q3 2025, and $7.0 million during Q2 2025.